Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

STAR: ultrafast universal RNA-seq aligner

Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Robust enumeration of cell subsets from tissue expression profiles

Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Inferring tumour purity and stromal and immune cell admixture from expression data

Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

High-throughput single-сell sequencing in cancer research

Jia, Q., Chu, H., Jin, Z., Long, H., & Zhu, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00990-4 · Cited by 157

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma

Lim, S. Y., Shklovskaya, E., Lee, J., Pedersen, B., Stewart, A., Ming, Z., Irvine, M., Shivalingam, B., Saw, R. P. M., Menzies, A. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36979-y · Cited by 161

Rational combinations of immunotherapy with radiotherapy in ovarian cancer

Herrera, F. G., Irving, M. B., Kandalaft, L. E., & Coukos, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30401-2 · Cited by 154

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor

Koblish, H. K., Wu, L., Wang, L.-C. S., Liu, P. C. C., Wynn, R., Rios‐Doria, J., Spitz, S., Liu, H., Volgina, A., Zolotarjova, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1156 · Cited by 155

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma

Zhang, C., Shen, H., Yang, T., Li, T., Liu, X., Wang, J., Liao, Z., Wei, J., Lu, J., Liu, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34877-3 · Cited by 163

Persistent mutation burden drives sustained anti-tumor immune responses

Niknafs, N., Balan, A., Cherry, C., Hummelink, K., Monkhorst, K., Shao, X. M., Belcaid, Z., Marrone, K. A., Murray, J. C., Smith, K. N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02163-w · Cited by 153

Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response

von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 144

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

Lauss, M., Donia, M., Svane, I. M., & Jönsson, G. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1130 · Cited by 145

Hallmarks of Resistance to Immune-Checkpoint Inhibitors

Karasarides, M., Cogdill, A. P., Robbins, P. B., Bowden, M., Burton, E. M., Butterfield, L. H., Cesano, A., Hammer, C., Haymaker, C., Horak, C. E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0586 · Cited by 154

Cancer Immunoediting in the Era of Immuno-oncology

Gubin, M. M., & Vesely, M. D. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1804 · Cited by 167

JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

Yoshino, T., Pentheroudakis, G., Mishima, S., Overman, M. J., Yeh, K., Baba, E., Naito, Y., Calvo, F. M., Saxena, A. K., Chen, L.-T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.299 · Cited by 142

Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches

Gupta, R. G., Li, F., Roszik, J., & Lizee, G. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1575 · Cited by 144

Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma

Zhang, N., Zhang, H., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, F., Liu, Z., et al. (2022) · Theranostics · doi:10.7150/thno.74281 · Cited by 142

Novel targets for immune-checkpoint inhibition in cancer

Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 150

Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile

Wang, T.-B., Guo, K., Zhang, D., Wang, H., Yin, J., Cui, H., & Wu, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110368 · Cited by 141

Advances and prospects of biomarkers for immune checkpoint inhibitors

Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 152

Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer

Wang, S., Zhang, Q., Yu, C., Cao, Y., Zuo, Y., & Yang, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa026 · Cited by 138

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis

Wu, Y., Xu, J., Du, C., Wu, Y., Xia, D., Lv, W., & Hu, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01161 · Cited by 143

Interpretable systems biomarkers predict response to immune-checkpoint inhibitors

Lapuente-Santana, Ó., van Genderen, M. N. G., Hilbers, P. A. J., Finotello, F., & Eduati, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100293 · Cited by 142

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy

Long, H., Jia, Q., Wang, L., Fang, W., Wang, Z., Jiang, T., Zhou, F., Zheng, J., Huang, J., Zhou, L., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.018 · Cited by 138

Development of therapeutic antibodies for the treatment of diseases

Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146

iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction

Ye, B., Fan, J., Xue, L., Yu, Z., Luo, P., Jiang, A., Xie, J., Li, Q., Liang, X., Tan, J., et al. (2025) · iMeta · doi:10.1002/imt2.70011 · Cited by 141

Evolution of delayed resistance to immunotherapy in a melanoma responder

Liu, D., Lin, J., Robitschek, E. J., Kasumova, G. G., Heyde, A., Shi, A., Kraya, A., Zhang, G., Moll, T. O. C., Frederick, D. T., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01331-8 · Cited by 139

PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis

Ping, Y., Shan, J., Qin, H., Li, F., Qu, J., Guo, R., Han, D. H., Wei, J., Liu, Y., Liu, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.08.003 · Cited by 142

Immune checkpoint blockade therapy

Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 134

RIG-I activation is critical for responsiveness to checkpoint blockade

Heidegger, S. M., Wintges, A., Stritzke, F., Bek, S., Steiger, K., Koenig, P.-A., Göttert, S., Engleitner, T., Öllinger, R., Nedelko, T., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8943 · Cited by 136

Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy

Zhang, Z., Chen, L., Chen, H., Zhao, J., Li, K., Sun, J., & Zhou, M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104207 · Cited by 135

The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer

Chow, A. T., Uddin, F. Z., Liu, M., Dobrin, A., Nabet, B. Y., Mangarin, L. M. B., Lavin, Y., Rizvi, H. A., Tischfield, S. E., Quintanal-Villalonga, À., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.12.001 · Cited by 141

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 138

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

Galsky, M. D., Saci, A., Szabó, P. M., Han, G. C., Grossfeld, G. D., Collette, S., Siefker-Radtke, A. O., Necchi, A., & Sharma, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4162 · Cited by 135

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

Chen, S.-H., Dominik, P. K., Stanfield, J., Ding, S., Yang, W., Kurd, N. S., Llewellyn, R. A., Heyen, J. R. R., Wang, C., Melton, Z., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003464 · Cited by 135

Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment

Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 137

Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer

Tello‐Lafoz, M., Srpan, K., Sanchez, E. E., Hu, J. Y., Remšík, J., Romin, Y., Calò, A., Hoen, D. R., Bhanot, U. K., Morris, L. G. T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.020 · Cited by 129

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy

Wang, P., Chen, Y., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672677 · Cited by 130

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer

van Dijk, N., Funt, S. A., Blank, C. U., Powles, T. B., Rosenberg, J. E., & van der Heijden, M. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.022 · Cited by 121

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

Boshuizen, J., Vredevoogd, D. W., Krijgsman, O., Ligtenberg, M. A., Blankenstein, S. A., de Bruijn, B., Frederick, D. T., Kenski, J. C. N., Parren, M., Brüggemann, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17739-8 · Cited by 122

High endothelial venules in cancer: Regulation, function, and therapeutic implication

Vella, G., Hua, Y., & Bergers, G. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.002 · Cited by 132

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma

Halse, H. M., Colebatch, A. J., Petrone, P., Henderson, M. A., Mills, J. K., Snow, H. A., Westwood, J. A., Sandhu, S. K., Raleigh, J., Behren, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28944-3 · Cited by 125

Computational Prediction and Validation of Tumor-Associated Neoantigens

Roudko, V., Greenbaum, B. D., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 123

Evolutionary dynamics of neoantigens in growing tumors

Lakatos, E., Williams, M. J., Schenck, R. O., Cross, W. C. H., Househam, J., Zapata, L., Werner, B., Gatenbee, C., Robertson‐Tessi, M., Barnes, C. P., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0687-1 · Cited by 118

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 124

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Pérez‐Guijarro, E., Yang, H. H., Araya, R. E., Meskini, R. E., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 119

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation

Lin, W., Chen, L., Zhang, H., Qiu, X., Huang, Q., Wan, F., Le, Z., Geng, S., Zhang, A., Qiu, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35710-7 · Cited by 119

IL-1β-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance

Han, Y., Zhang, Y., Pan, Y., Zheng, X., Liao, K. L., Mo, H., Sheng, H., Wu, Q., Liu, Z., Zeng, Z.-L., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.05.011 · Cited by 120

Predictive biomarkers for response to immune checkpoint inhibition

Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 118

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Joung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 119

FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells

Shen, J. Z., Qiu, Z., Wu, Q., Finlay, D., Garcia, G., Sun, D., Rantala, J., Barshop, W., Hope, J. L., Gimple, R. C., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.042 · Cited by 113

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Ng, H. H. M., Lee, R. Y., Goh, S., Tay, I. S. Y., Lim, X., Lee, B. T. K., Chew, V., Li, H., Tan, B., Lim, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000987 · Cited by 115

GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation

Zhang, H., Zhan, X., & Li, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25006-7 · Cited by 120

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

Yang, S. Y. C., Lien, S. C., Wang, B. X., Clouthier, D., Hanna, Y., Cirlan, I., Zhu, K., Bruce, J. P., Ghamrasni, S. E., Iafolla, M. A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25432-7 · Cited by 119

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1537581 · Cited by 115

Turning tumors from cold to inflamed to improve immunotherapy response

Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 118

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells

Wang, K., Coutifaris, P., Brocks, D., Wang, G., Azar, T., Solis, S., Nandi, A., Anderson, S., Han, N. A., Manne, S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.007 · Cited by 127

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma

Josefsson, S. E., Beiske, K., Blaker, Y. N., Førsund, M. S., Holte, H., Østenstad, B., Kimby, E. K., Köksal, H., Wälchli, S., Bai, B., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0351 · Cited by 118

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

Alborelli, I., Leonards, K., Rothschild, S. I., Leuenberger, L. P., Prince, S. S., Mertz, K. D., Poechtrager, S., Buess, M., Zippelius, A., Laubli, H. P., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5344 · Cited by 116

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

Feng, K., Liu, Y., Zhao, Y., Yang, Q., Dong, L., Liu, J., Li, X., Zhao, Z., Mei, Q., & Han, W. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000367 · Cited by 118

YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer

Tsuchiya, K., Yoshimura, K., Inoue, Y., Iwashita, Y., Yamada, H., Kawase, A., Watanabe, T., Tanahashi, M., Ogawa, H., Funai, K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1962656 · Cited by 114

CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy

Franken, A., Bila, M., Mechels, A., Kint, S., Dessel, J. V., Pomella, V., Vanuytven, S., Philips, G., Bricard, O., Xiong, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.007 · Cited by 128

The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis

Roufas, C., Chasiotis, D., Makris, A., Efstathiades, C., Dimopoulos, C., & Zaravinos, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00027 · Cited by 114

Majority of B2M -Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High

Middha, S., Yaeger, R. D., Shia, J., Stadler, Z. K., King, S., Guercio, S., Paroder, V., Bates, ‬. D. B., Rana, S., Diaz, L. A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00321 · Cited by 116

Transcriptomics and solid tumors: The next frontier in precision cancer medicine

Tsimberidou, A. M., Fountzilas, E., Bleris, L. G., & Kurzrock, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.007 · Cited by 118

Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma

Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, R., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 119

MHC-I genotype and tumor mutational burden predict response to immunotherapy

Goodman, A. M., Castro, A., Pyke, R. M., Okamura, R., Kato, S., Riviere, P. J., Frampton, G. M., Sokol, E. S., Zhang, X., Ball, E. D., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00743-4 · Cited by 112

The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response

Wang, G., Xu, D., Zhang, Z., Li, X., Sun, J., Sun, J., Li, X., Li, X., Zhou, M., & Zheng, T. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00200-4 · Cited by 118

Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response

Coulton, A., Murai, J., Qian, D., Thakkar, K., Lewis, C. E., & Litchfield, K. (2024) · Nature Communications · doi:10.1038/s41467-024-49885-8 · Cited by 125

Common germline variants of the human APOE gene modulate melanoma progression and survival

Ostendorf, B. N., Bilanovic, J., Adaku, N., Tafreshian, K. N., Tavora, B., Vaughan, R. D., & Tavazoie, S. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0879-3 · Cited by 108

Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer

Wang, S., Xiong, Y., Zhang, Q., Su, D., Yu, C., Cao, Y., Pan, Y., Lu, Q., Zuo, Y., & Yang, L. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa311 · Cited by 108

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

Grossman, J. E., Vasudevan, D., Joyce, C. E., & Hildago, M. (2021) · Oncogene · doi:10.1038/s41388-020-01611-6 · Cited by 107

Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy

Lu, M., Zhao, B., Liu, M., Wu, L., Li, Y., Zhai, Y., & Shen, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00193-0 · Cited by 113

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Yin, S., Chen, Z., Chen, D., & Yan, D. (2023) · Theranostics · doi:10.7150/thno.80091 · Cited by 115

The immune system profoundly restricts intratumor genetic heterogeneity

Milo, I., Bedora-Faure, M., Garcia, Z., Thibaut, R., Perié, L., Shakhar, G., Deriano, L., & Bousso, P. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat1435 · Cited by 113

Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure

Lin, Z., Huang, L., Li, S., Gu, J., Cui, X., & Zhou, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-78560-3 · Cited by 111

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

Yue, D., Liu, W., Chen, C., Zhang, T., Ma, Y., Cui, L., Gu, Y., Bei, T., Zhao, X., Zhang, B., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-106 · Cited by 109

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas

Kunz, M., Loeffler‐Wirth, H., Dannemann, M., Willscher, E., Doose, G., Kelso, J. F., Kottek, T., Nickel, B., Hopp, L., Landsberg, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0385-y · Cited by 111

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches

Song, D., Powles, T. B., Shi, L., Zhang, L., Ingersoll, M. A., & Lu, Y. (2019) · The Journal of Pathology · doi:10.1002/path.5306 · Cited by 108

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer

Chen, H., Chong, W., Teng, C., Yao, Y., Wang, X., & Li, X. (2019) · Cancer Science · doi:10.1111/cas.14113 · Cited by 106

Radioimmunotherapy for the treatment of head and neck cancer

Karam, S. D., & Raben, D. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30306-7 · Cited by 104

SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion

Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.008 · Cited by 113

seq-ImmuCC: Cell-Centric View of Tissue Transcriptome Measuring Cellular Compositions of Immune Microenvironment From Mouse RNA-Seq Data

Chen, Z., Quan, L., Huang, A., Zhao, Q., Yao, Y., Yuan, X., Shen, Q., Shang, J., Ben, Y., Qin, F. X.-F., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01286 · Cited by 105

The tumour microenvironment as an integrated framework to understand cancer biology

Burgos‐Panadero, R., Lucantoni, F., Gamero‐Sandemetrio, E., de la Cruz‐Merino, L., Álvaro, T., & Noguera, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.07.010 · Cited by 106

Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma

He, Q., Yang, J., & Jin, Y. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac291 · Cited by 102

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

Aspeslagh, S., Morel, D., Soria, J., & Postel-Vinay, S. C. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy050 · Cited by 105

An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors

Lu, Y., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V. V., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 105

Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling

Antonelli, A. C., Binyamin, A., Hohl, T. M., Glickman, M. S., & Redelman‐Sidi, G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004421117 · Cited by 104

Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

Litchfield, K., Reading, J. L., Lim, E. L., Xu, H., Liu, P., Bakir, M. A., Wong, Y. N. S., Rowan, A., Funt, S. A., Merghoub, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17526-5 · Cited by 102

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma

Zhuo, M., Guan, Y., Yang, X., Hong, L., Wang, Y., Li, Z., Chen, R., Abbas, H. A., Chang, L., Gong, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0556 · Cited by 99

Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response

Roelands, J. P., Hendrickx, W., Zoppoli, G. M., Mall, R., Saad, M., Halliwill, K. D., Curigliano, G., Rinchai, D., Decock, J. V., Delogu, L. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000617 · Cited by 100

Single‐cell transcriptomic analysis reveals circadian rhythm disruption associated with poor prognosis and drug‐resistance in lung adenocarcinoma

He, L., Fan, Y., Zhang, Y., Tu, T.-T., Zhang, Q., Yuan, F., & Cheng, C. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12803 · Cited by 98

Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models

Verma, S., Budhu, S., Serganova, I. S., Dong, L., Mangarin, L. M. B., Khan, J. F., Bah, M. A., Assouvie, A., Marouf, Y., Schulze, I., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177606 · Cited by 105

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

D’Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., Lucia, M. D., Avalle, L., Vitale, R., Leuzzi, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10594-2 · Cited by 98

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

Zhang, N., Yang, X., Piao, M., Xun, Z., Wang, Y., Ning, C., Zhang, L., Zhang, L., Wang, S., Wang, S., et al. (2024) · Biomarker Research · doi:10.1186/s40364-023-00535-z · Cited by 104

Mechanisms of immune checkpoint inhibitor-mediated liver injury

Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98

HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors

Song, K., Oh, S. J., Kim, S., Cho, H., Lee, H.-J., Song, J. S., Chung, J., Cho, E., Lee, J., Jeon, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14259-y · Cited by 96

Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma

Tian, Y., Xiao, H., Yang, Y., Zhang, P., Yuan, J., Zhang, W., Chen, L., Fan, Y., Zhang, J., Cheng, H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01706-6 · Cited by 97

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer

Xiong, D., Wang, Y., Singavi, A. K., Mackinnon, A. C., George, B., & You, M. (2018) · iScience · doi:10.1016/j.isci.2018.10.021 · Cited by 94

PTEN loss correlates with T cell exclusion across human cancers

Lin, Z., Huang, L., Li, S. L., Gu, J., Cui, X., & Zhou, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08114-x · Cited by 97

Multiomics and spatial mapping characterizes human CD8 + T cell states in cancer

Naulaerts, S., Datsi, A., Borràs, D., Antoranz, A., Messiaen, J., Vanmeerbeek, I., Sprooten, J., Laureano, R. S., Govaerts, J., Panovska, D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1016 · Cited by 99

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities

Wang, X., Lamberti, G., Federico, A. D., Alessi, J. V., Ferrara, R., Sholl, M. L., Awad, M. M., Vokes, N. I., & Ricciuti, B. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.007 · Cited by 99

Abstract 2988: Immunogenomic analyses of tumor cells and microenvironment in patients with advanced melanoma before and after treatment with nivolumab

Chan, T. A.-T., Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Sims, J. S., Hodi, F. S., Martín‐Algarra, S., Sharfman, W. H., Bhatia, S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2988

Abstract 1125: Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Alban, T. J., Riaz, N., Parthasarathy, P. B., Makarov, V., Kendall, S., Yoo, S., Shah, R., Weinhold, N., Srivastava, R. M., Ma, X., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-1125 · Cited by 1

Tumor control

Visan, I. (2017) · Nature Immunology · doi:10.1038/ni.3878

Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma

Yusko, E. C., Vignali, M., Wilson, R. K., Mardis, E. R., Hodi, F. S., Horak, C. E., Chang, H., Woods, D. M., Robins, H. S., & Weber, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0226 · Cited by 59

Editors' Picks

(2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.11.011